‘There Is Always Room For Improvement’: Celltrion Reflects On A Decade Of European Biosimilars
Senior VP And Head Of Marketing Kevin Byoung Seo Choi Talks To Generics Bulletin
Executive Summary
Marking a decade since Celltrion’s Remsima version of infliximab became the first monoclonal antibody biosimilar approved in Europe, Kevin Byoung Seo Choi, senior vice president and head of the marketing division at Celltrion Healthcare, talks to Generics Bulletin about the firm’s progress so far and the “room for improvement” that the company perceives in areas such as regulation, market access and pricing, supply chain and procurement – as well as what the future holds for the Korean biosimilars giant.